Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study Investigating the Safety and Efficacy of Omnitram in Diabetic Neuropathy

NCT03664921 is registered in ClinicalTrials.gov with Syntrix Biosystems, Inc. as lead sponsor.

NCT NCT03664921
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03664921 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study Investigating the Safety and Efficacy of Omnitram in Diabetic Neuropathy
Lead sponsor
Syntrix Biosystems, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 15, 2018
Completion date
August 17, 2020
Enrollment
55 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic neuropathies, neuropathic pain, pain, chronic